# LABCORP HOLDINGS INC. (LH)

Informational only - not investment advice.

CIK: 0000920148
SIC: 8071 Services-Medical Laboratories
SIC breadcrumb: [Services](/division/I/) > [SIC Major Group 80](/major-group/80/) > [SIC 8071 Services-Medical Laboratories](/industry/8071/)
Latest 10-K filed: 2026-02-24
SEC page: https://www.sec.gov/edgar/browse/?CIK=920148
Filing source: https://www.sec.gov/Archives/edgar/data/920148/000092014826000111/lh-20251231.htm

## At a glance

FY2025 · period end 2025-12-31 · filed 2026-02-24 · accession 0000920148-26-000111 · source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000920148.json

| Metric | Value | FY | Provenance |
| --- | ---: | ---: | --- |
| Revenue | 13,951,700,000 USD | 2025 | verified |
| Net income | 876,500,000 USD | 2025 | verified |
| Assets | 18,392,700,000 USD | 2025 | verified |
| Free cash flow | 1,206,000,000 USD | 2025 | computed |
| Net margin | 6.28% | 2025 | computed |
| Operating margin | 9.92% | 2025 | computed |
| Revenue YoY | +7.25% | 2025 | computed |
| ROE | 10.17% | 2025 | computed |

Computed values are grepcent-computed from the verified facts above and may differ from ratios the company itself reports. Free cash flow = operating cash flow − capital expenditures. Net margin = net income ÷ revenue. Operating margin = operating income ÷ revenue. Revenue YoY = FY2025 revenue ÷ FY2024 revenue − 1 (consecutive fiscal years only). ROE = net income ÷ period-end stockholders' equity.

No market price, no rating, no forecast on this site. Not investment advice.

### Peer percentile fingerprint

| Ratio | LH | Peer median | Percentile | N |
| --- | ---: | ---: | ---: | ---: |
| Net margin | 6.3% | -7.7% | 82 | 12 |
| Operating margin | 9.9% | -10.3% | 82 | 12 |
| Revenue growth | 7.2% | 13.8% | 25 | 13 |
| FCF margin | 8.6% | 4.7% | 80 | 11 |
| ROE | 10.2% | -7.0% | 92 | 13 |
| ROA | 4.8% | -5.6% | 92 | 14 |
| Liabilities / equity | 1.13 | 0.40 | 67 | 13 |
| Current ratio | 1.42 | 5.05 | 15 | 14 |

Percentile = share of the N covered peers reporting that ratio whose value is lower (ties counted half); computed among grepcent-covered companies in SIC industry 8071 Services-Medical Laboratories, not the whole market. A higher percentile means a higher value of the ratio, not a better company. Ratios with fewer than 8 reporting peers are omitted. Latest reported values per company; fiscal periods may differ. Descriptive arithmetic - not a score, rating, or ranking.

## Selected Fundamentals
| Metric | Value | Unit | FY | Filed |
| --- | ---: | --- | ---: | --- |
| Revenue | 13951700000 | USD | 2025 | 2026-02-24 |
| Net income | 876500000 | USD | 2025 | 2026-02-24 |
| Assets | 18392700000 | USD | 2025 | 2026-02-24 |

## Financials

Annual standardized facts from SEC companyfacts as of latest extracted filing date 2026-02-24. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000920148.json. Derived margins, ratios, and free cash flow are computed from the extracted annual SEC facts.

| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | 9,552,900,000 | 10,308,000,000 | 11,333,400,000 | 11,554,800,000 | 13,978,500,000 | 13,136,100,000 | 11,863,900,000 | 12,161,600,000 | 13,008,900,000 | 13,951,700,000 |
| Net income | 711,800,000 | 1,227,100,000 | 883,700,000 | 823,800,000 | 1,556,100,000 | 2,377,300,000 | 1,279,100,000 | 418,000,000 | 746,000,000 | 876,500,000 |
| Operating income | 1,270,600,000 | 1,305,200,000 | 1,325,700,000 | 1,330,200,000 | 2,445,400,000 | 3,048,600,000 | 1,436,500,000 | 725,600,000 | 1,086,700,000 | 1,384,700,000 |
| Gross profit | 2,854,000,000 | 3,091,800,000 | 3,176,400,000 | 3,252,500,000 | 4,952,800,000 | 4,992,400,000 | 3,708,900,000 | 3,364,900,000 | 3,624,400,000 | 4,012,500,000 |
| Diluted EPS | 6.82 | 11.81 | 8.61 | 8.35 | 15.88 | 24.39 | 13.97 | 4.77 | 8.84 | 10.46 |
| Operating cash flow | 1,197,100,000 | 1,498,100,000 | 1,305,400,000 | 1,444,700,000 | 2,135,300,000 | 3,109,600,000 | 1,955,900,000 | 1,327,700,000 | 1,585,800,000 | 1,640,500,000 |
| Capital expenditures | 278,900,000 | 312,900,000 | 379,800,000 | 400,200,000 | 381,700,000 | 421,500,000 | 429,300,000 | 453,600,000 | 489,900,000 | 434,500,000 |
| Dividends paid |  |  |  |  |  |  | 195,200,000 | 254,000,000 | 243,100,000 | 240,700,000 |
| Share buybacks | 43,900,000 | 338,100,000 | 700,000,000 | 450,000,000 | 100,000,000 | 1,668,500,000 | 1,100,000,000 | 1,000,000,000 | 250,100,000 | 450,000,000 |
| Assets | 14,247,000,000 | 16,673,000,000 | 16,185,300,000 | 18,046,400,000 | 20,071,700,000 | 20,385,400,000 | 20,155,100,000 | 16,725,100,000 | 18,379,000,000 | 18,392,700,000 |
| Liabilities | 8,726,000,000 | 9,848,100,000 | 9,194,800,000 | 10,459,300,000 | 10,614,400,000 | 10,091,400,000 | 10,039,600,000 | 8,834,600,000 | 10,312,500,000 | 9,756,000,000 |
| Stockholders' equity | 5,518,200,000 | 6,804,100,000 | 7,048,300,000 | 7,643,900,000 | 9,436,600,000 | 10,273,400,000 | 10,096,600,000 | 7,875,000,000 | 8,052,200,000 | 8,619,800,000 |
| Cash and cash equivalents | 433,600,000 | 316,600,000 | 426,800,000 | 337,500,000 | 1,320,800,000 | 1,472,700,000 | 320,600,000 | 536,800,000 | 1,518,700,000 | 532,300,000 |
| Free cash flow | 918,200,000 | 1,185,200,000 | 925,600,000 | 1,044,500,000 | 1,753,600,000 | 2,688,100,000 | 1,526,600,000 | 874,100,000 | 1,095,900,000 | 1,206,000,000 |

### Ratios

ROE and ROA use period-end equity/assets. Liabilities / equity uses total liabilities divided by stockholders' equity. Current ratio uses current assets divided by current liabilities when both are reported.

| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net margin | 7.45% | 11.90% | 7.80% | 7.13% | 11.13% | 18.10% | 10.78% | 3.44% | 5.73% | 6.28% |
| Operating margin | 13.30% | 12.66% | 11.70% | 11.51% | 17.49% | 23.21% | 12.11% | 5.97% | 8.35% | 9.92% |
| Return on equity | 12.90% | 18.03% | 12.54% | 10.78% | 16.49% | 23.14% | 12.67% | 5.31% | 9.26% | 10.17% |
| Return on assets | 5.00% | 7.36% | 5.46% | 4.56% | 7.75% | 11.66% | 6.35% | 2.50% | 4.06% | 4.77% |
| Liabilities / equity | 1.58 | 1.45 | 1.30 | 1.37 | 1.12 | 0.98 | 0.99 | 1.12 | 1.28 | 1.13 |
| Current ratio | 1.36 | 1.25 | 1.51 | 1.12 | 1.66 | 1.92 | 1.50 | 1.17 | 1.44 | 1.42 |

## As-reported value updates

21 tracked differences above grepcent's stated thresholds were found between the earliest XBRL-filed value and the value currently on file for the same fiscal period.

Ledger: /company/LH/revisions/


## Quarterly

Quarterly standardized facts from SEC companyfacts as of latest extracted filing date 2026-08-05. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000920148.json.

Flow metrics use discrete quarter-length periods from 10-Q/10-Q/A filings. Q4 revenue and net income are derived only when annual FY and nine-month YTD facts exist for the same fiscal year; derived Q4 values are labeled. EPS Q4 is not derived.

| Quarter | End date | Revenue | Net income | Diluted EPS | Method |
| --- | --- | ---: | ---: | ---: | --- |
| 2022-Q2 | 2022-06-30 |  |  | 3.87 | reported discrete quarter |
| 2022-Q3 | 2022-09-30 |  |  | 3.90 | reported discrete quarter |
| 2023-Q1 | 2023-06-30 |  |  | 2.12 | reported discrete quarter |
| 2023-Q3 | 2023-09-30 | 3,056,800,000 | 183,600,000 | 2.11 | reported discrete quarter |
| 2023-Q4 | 2023-12-31 | 3,033,300,000 | -166,800,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2024-Q1 | 2024-03-31 | 3,176,600,000 | 228,300,000 | 2.69 | reported discrete quarter |
| 2024-Q2 | 2024-06-30 | 3,220,900,000 | 205,600,000 | 2.43 | reported discrete quarter |
| 2024-Q3 | 2024-09-30 | 3,282,000,000 | 169,600,000 | 2.00 | reported discrete quarter |
| 2024-Q4 | 2024-12-31 | 3,329,400,000 | 143,600,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2025-Q1 | 2025-03-31 | 3,345,100,000 | 213,000,000 | 2.52 | reported discrete quarter |
| 2025-Q2 | 2025-06-30 | 3,527,300,000 | 238,300,000 | 2.84 | reported discrete quarter |
| 2025-Q3 | 2025-09-30 | 3,563,500,000 | 261,500,000 | 3.12 | reported discrete quarter |
| 2025-Q4 | 2025-12-31 | 3,515,800,000 | 164,900,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2026-Q1 | 2026-03-31 | 3,537,600,000 | 278,000,000 | 3.35 | reported discrete quarter |
| 2026-Q2 | 2026-06-30 | 3,731,100,000 | 299,100,000 | 3.64 | reported discrete quarter |

## Filed narrative (10-K & 10-Q)

## Business

Verbatim Item 1 Business section from LH's latest 10-K: [/company/LH/business/](/company/LH/business/).

## Risk Factors

Verbatim Item 1A Risk Factors from LH's latest 10-K: [/company/LH/risk-factors/](/company/LH/risk-factors/).

## Latest quarter (10-Q)

Latest 10-Q source: https://www.sec.gov/Archives/edgar/data/920148/000092014826000175/lh-20260630.htm

Extracted structurally from real Item 2 body heading to real Item 3/4 boundary. Published MD&A gate trimmed front/tail over-capture.
Confidence: high
Filing date: 2026-08-05
Report date: 2026-06-30

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

FORWARD-LOOKING STATEMENTS

In this Quarterly Report on Form 10-Q (Quarterly Report), Labcorp® Holdings Inc. together with its subsidiaries (Labcorp, LHI or the Company) has made, and from time to time may otherwise make in its public filings, press releases, and discussions by Company management, forward-looking statements concerning the Company’s operations, performance, and financial condition, as well as its strategic objectives. Some of these forward-looking statements relate to future events and expectations and can be identified by the use of forward-looking words such as “believes”, “expects”, “may”, “will”, “should”, “seeks”, “approximately”, “intends”, “plans”, “estimates”, or “anticipates” or the negative of those words or other comparable terminology. Such forward-looking statements speak only as of the time they are made and are subject to various risks and uncertainties and the Company claims the protection afforded by the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those currently anticipated due to a number of factors in addition to those discussed elsewhere herein, including in the “Risk Factors” section of the Annual Report, and in the Company’s other public filings, press releases, and discussions with Company management, including:

1.changes in government and third-party payer regulations, reimbursement, or coverage policies or other future reforms in the U.S. healthcare system (or in the interpretation of current regulations), new insurance or payment systems, including state, regional or private insurance cooperatives (e.g., health insurance exchanges) affecting governmental and third-party coverage or reimbursement for commercial laboratory testing, including the impact of the U.S. Protecting Access to Medicare Act;

2.significant monetary damages, and penalties, and/or exclusion from or ineligibility to participate in government programs, among other adverse consequences, arising from enforcement of anti-fraud and abuse laws and other laws applicable to the Company in jurisdictions in which the Company conducts business;

3.significant fines, penalties, costs, unanticipated compliance expenditures, and/or damage to the Company’s reputation arising from the failure to comply with applicable privacy and security laws and regulations;

4.loss or suspension of a license or imposition of fines or penalties under, or future changes in or interpretations of the U.S. Clinical Laboratory Improvement Amendments of 1988, Medicare, Medicaid, or other national, state, or local laws or regulations of the U.S. and other countries where the Company operates laboratories;

5.penalties or loss of license arising from the failure to comply with applicable occupational and workplace safety laws and regulations, including the U.S. Occupational Safety and Health Administration requirements, the U.S. Needlestick Safety and Prevention Act, and similar laws and regulations in jurisdictions in which the Company conducts business;

6.fines, unanticipated compliance expenditures, suspension of manufacturing, enforcement actions, damage to the Company’s reputation, injunctions, or criminal prosecution arising from failure to maintain compliance with Current Good Manufacturing Practice regulations and similar requirements of various regulatory agencies in jurisdictions in which the Company conducts business;

7.sanctions or other remedies, including fines, unanticipated compliance expenditures, enforcement actions, injunctions or criminal prosecution arising from failure to comply with the U.S. Animal Welfare Act or applicable national, state, and local laws and regulations in jurisdictions in which the Company conducts business;

8.changes in testing guidelines or recommendations by government agencies, medical specialty societies, and other authoritative bodies affecting the development, validation, approval, clearance, commercialization, or utilization of laboratory tests;

9.changes in and failure to comply with the applicable regulations of pharmaceutical and medical device regulators affecting the approval, availability of, and the selling and marketing of diagnostic tests, including laboratory-developed tests, drug development, or the conduct of drug development and medical device and diagnostic studies and trials, including regulations and policies of the U.S. Food and Drug Administration, the U.S. Department of Agriculture, the Medicines and Healthcare Products Regulatory Agency in the U.K., the National Medical Products Administration in China, the Pharmaceutical and Medical Devices Agency in Japan, the European Union, the European Medicines Agency, and similar regulations and policies of agencies in other jurisdictions in which the Company conducts business;

10.changes in government regulations pertaining to the pharmaceutical, biotechnology, medical device, and diagnostic industries, changes in reimbursement of pharmaceutical products, or reduced spending on research and development by pharmaceutical, biotechnology, medical device, and diagnostic customers;

11.liabilities that result from the failure to comply with corporate governance requirements;

12.increased competition, including price competition, potential reduction in rates in response to price transparency initiatives and consumerism, competitive bidding and/or changes or reductions to fee schedules, and competition from companies that do not comply with existing applicable laws or regulations or otherwise disregard compliance standards in the industry;

13.changes in payer mix or payment structure or process, including insurance carrier participation in health insurance exchanges, an increase in capitated reimbursement mechanisms, the impact of clearinghouses on the claims reimbursement

24

TABLE OF CONTENTS

process, the impact of a shift to consumer-driven health plans or plans carrying an increased level of member cost-sharing, and adverse changes in payer reimbursement or payer coverage policies (implemented directly or through a third-party utilization management organization) related to specific diagnostic tests, categories of testing, or testing methodologies;

14.failure to retain or attract business from MCOs as a result of changes in strategy or business models;

15.failure to obtain and retain new customers, an unfavorable change in the mix of testing services ordered, or a reduction in tests ordered, specimens submitted, or services requested by existing customers, and delays in payments from customers;

16.consolidation and convergence of customers, competitors, and suppliers, potentially causing material shifts in insourcing, utilization, pricing, reimbursement, and supply chain access;

17.failure to invest in or effectively develop and deploy new systems, system modifications or enhancements required in response to evolving market, business, and customer trends and needs;

18.failure to identify, successfully close, and effectively integrate and/or manage acquisitions of new businesses or failure to maintain key customers and/or employees as a result of uncertainty surrounding the integration of acquisitions;

19.inability to achieve the expected benefits and synergies of newly acquired businesses, including due to items not discovered in the due diligence process, and the impact on the Company’s cash position, levels of indebtedness, and stock price;

20.termination, loss, delay, reduction in scope, or increased costs of contracts;

21.liability arising from errors or omissions in the performance of testing and other services or other contractual arrangements;

22.changes or disruption in the provision or transportation of services or supplies provided by third parties; or their termination for failure to follow the Company’s performance standards and requirements;

23.damage or disruption to the Company’s facilities;

24.impact on the Company’s reputation, or business, from acts of animal rights activists or potential harm, liability, or operational disruptions arising from, or increased regulations and restrictions, of animal research activities;

25.adverse results in litigation matters;

26.inability to attract, retain, and develop experienced and qualified personnel, including personnel in key roles and critical positions, due to increased competition for talent, wage growth, or other market factors beyond the Company’s control;

27.failure to develop or acquire licenses for new or improved technologies, such as point-of-care testing, mobile health technologies, and digital pathology, or potential use of new technologies by customers and/or consumers to perform their own tests;

28.substantial costs arising from the inability to commercialize newly licensed tests or technologies or to obtain appropriate coverage or reimbursement for such tests;

29.failure to obtain, maintain, and enforce intellectual property rights for protection of the Company’s offerings and defend against challenges to those rights;

30.scope, validity, and enforceability of patents and other proprietary rights held by third parties that may impact the Company’s ability to develop, perform, or market the Company’s offerings or operate its business;

31.business interruption, receivables impairment, delays in cash collection impacting days sales outstanding, supply chain disruptions or inventory obsolescence, increases in the Company’s material costs or other operating costs, or other impacts on the business due to natural disasters, adverse weather, geopolitical events, public health crises, and other events beyond the Company’s control;

32.discontinuation or recalls of existing products used in the performance of testing;

33.a failure in the information technology systems of the Company or newly-acquired businesses, the failure of the Company or its third-party suppliers and vendors to maintain the security of their information technology systems or to protect against cybersecurity incidents, failures in the development and implementation of the Company’s automation platforms, or adverse effects from the use of or regulation of artificial intelligence and machine learning tools;

34.business interruption, increased costs, and other adverse effects on the Company’s operations due to the unionization of employees, union strikes, work stoppages, general labor unrest, or failure to comply with labor or employment laws;

35.failure to maintain the Company’s days sales outstanding levels, cash collections (in light of increasing levels of patient responsibility), profitability and/or reimbursement arising from unfavorable changes in third-party payer policies, payment delays introduced by third-party utilization management organizations, and increasing levels of patient payment responsibility;

36.impact on the Company’s revenues, cash collections, and the availability of credit for general liquidity or other financing needs arising from a significant deterioration in the economy or financial markets or in the Company’s credit ratings by S&P and/or Moody’s;

37.failure to maintain the expected capital structure for the Company, including failure to maintain the Company’s investment grade rating, or leverage ratio covenants under its revolving credit facility;

38.changes in reimbursement by foreign governments and foreign currency fluctuations;

39.inability to obtain certain billing information from physicians, resulting in increased costs and complexity, a temporary disruption in receipts, and ongoing reductions in reimbursements and revenues;

40.expenses and risks associated with international operations, including, but not limited to, compliance with the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act, other applicable anti-corruption laws and regulations, trade sanction laws and regulations, a

[Excerpt truncated for page length; source filing is linked above.]

## Latest 10-K MD&A (excerpt)

Latest 10-K Item 7 source: https://www.sec.gov/Archives/edgar/data/920148/000092014826000111/lh-20251231.htm
Complete FY 2025 MD&A: /company/LH/mda/fy2025/

Extracted structurally from real Item 7 body heading to real Item 7A/8 boundary. Published MD&A gate trimmed front/tail over-capture.
Confidence: high
Filing date: 2026-02-24
Report date: 2025-12-31

Item 7.       MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

GENERAL (dollars in millions)

For the year ended December 31, 2025, the Company’s revenues were $13,951.7, an increase of 7.2% from $13,008.9 for the corresponding period in 2024. The 7.2% increase in revenues for the year ended December 31, 2025, as compared to the corresponding period in 2024, was primarily due to organic revenue of 4.4%, acquisitions, net of divestitures of 2.5%, and favorable foreign currency translation of 0.4%.

The Company defines organic growth as the increase in revenue excluding the year over year impact of acquisitions, divestitures, and currency. Acquisition and divestiture impact is considered for a 12-month period following the close of each transaction.

On June 30, 2023, the Company completed the Spin-off. The TSA dated June 29, 2023 between Fortrea and LCAH expired on June 30, 2025, and all services provided under the TSA terminated on or before the expiration date.

On July 4, 2025, the U.S. government enacted the OBBBA, which includes provisions addressing regulations and federal funding affecting healthcare. These provisions include, but are not limited to, changes to Medicaid and the ACA, and could lead to revised regulatory requirements and reduced federal funding. As a result of these changes, the Company could experience a decline in utilization of its diagnostics testing services due to a reduction in overall insurance coverage, which may cause the Company’s revenue to decrease. However, the Company currently believes any such reduction would not likely have a material impact on its results of operations in future periods. The potential impacts described above represent the Company’s assessment at this time, and the Company will continue to evaluate the impact of the OBBBA on its business and operations, if any, as the legislation’s provisions continue to become effective through 2028.

RESULTS OF OPERATIONS (dollars in millions)

The following tables present the financial measures that management considers to be the most significant indicators of the Company’s performance. For the discussion of 2024 results and comparison with 2023 results refer to “Management’s Discussion and Analysis of Financial Conditions and Results of Operations” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024.

Revenues

[[GREPCENT_TABLE]]
[["","Year Ended December 31,"],["","2025","","2024","","","","Change"],["Dx","$","10,876.5","","","$","10,144.3","","","","","7.2","%"],["BLS","3,098.2","","","2,922.6","","","","","6.0","%"],["Intercompany eliminations and other","(23.0)","","","(58.0)","","","","","60.4","%"],["Total","$","13,951.7","","","$","13,008.9","","","","","7.2","%"]]
[[/GREPCENT_TABLE]]

Dx revenues for the year ended December 31, 2025, were $10,876.5, an increase of 7.2% compared to revenues of $10,144.3 in the corresponding period in 2024. The increase was primarily due to organic revenue of 4.1% and acquisitions, net of divestitures of 3.2%, partially offset by unfavorable foreign currency translation of 0.1%.

Dx total volume, measured by requisitions, increased by 3.7%, as organic volume increased by 2.2% and acquisition volume, net of divestitures, contributed 1.5%. Price/mix increased by 3.5% due to organic growth of 1.9% and acquisitions, net of divestitures, of 1.7%, partially offset by unfavorable foreign currency translation of 0.1%.

BLS revenues for the year ended December 31, 2025, were $3,098.2, an increase of 6.0% over revenues of $2,922.6 in the corresponding period in 2024. The increase in revenues was primarily due to organic growth of 4.0% and favorable foreign currency translation of 2.0%.

38

TABLE OF CONTENTS

Cost of Revenues

[[GREPCENT_TABLE]]
[["","Year Ended December 31,"],["","2025","","2024","","","","Change"],["Cost of revenues","$","9,939.2","","$","9,384.5","","","","5.9","%"],["Cost of revenues as a percentage of revenues","71.2","%","","72.1","%"]]
[[/GREPCENT_TABLE]]

Cost of revenues increased 5.9% for the year ended December 31, 2025, as compared with corresponding period in 2024, and decreased as a percentage of revenues to 71.2% for the year ended December 31, 2025, as compared to 72.1% for the corresponding period in 2024. This decrease was primarily due to operational efficiencies and the impact from revenue growth, including the performance of Invitae.

Selling, General, and Administrative Expenses

[[GREPCENT_TABLE]]
[["","Year Ended December 31,"],["","2025","","2024","","","","Change"],["Selling, general, and administrative expenses","$","2,216.3","","$","2,230.0","","","","(0.6)","%"],["Selling, general, and administrative expenses as a percentage of revenues","15.9","%","","17.1","%"]]
[[/GREPCENT_TABLE]]

Selling, general, and administrative expenses as a percentage of revenues decreased to 15.9% for the year ended December 31, 2025, as compared to 17.1% for the year ended December 31, 2024. The decrease was primarily due to growth in demand as the Company leveraged the growth of its revenues and a decrease in costs related to the Spin-off, partially offset by higher personnel costs and the impact from Invitae.

Amortization of Intangibles and Other Assets

[[GREPCENT_TABLE]]
[["","Year Ended December 31,"],["","2025","","2024","","","","Change"],["Amortization of intangibles and other assets","$","280.0","","","$","256.4","","","","","9.2","%"]]
[[/GREPCENT_TABLE]]

The increase in amortization of intangibles and other assets primarily reflects additional amortization for assets acquired subsequent to December 31, 2024.

Goodwill and Other Asset Impairments

[[GREPCENT_TABLE]]
[["","Years Ended December 31,"],["","2025","","2024","","","","Change"],["Goodwill and other asset impairments","$","4.3","","","$","5.3","","","","","(18.9)","%"]]
[[/GREPCENT_TABLE]]

The impairment charges for the year ended December 31, 2025, were primarily due to the write-off of certain facility-related assets and capitalized software costs. The impairment charges for the year ended December 31, 2024, were primarily due to the decommissioning of an information system and a robotic asset.

Restructuring and Other Charges

[[GREPCENT_TABLE]]
[["","Year Ended December 31,"],["","2025","","2024","","","","Change"],["Restructuring and other charges","$","127.2","","","$","46.0","","","","","176.5","%"]]
[[/GREPCENT_TABLE]]

For the year ended December 31, 2025, the Company recorded net restructuring charges of $127.2, including $105.5 of charges associated with the restructuring of ED. The charges were comprised of $101.3 in long-lived asset impairment and other non-cash charges, $27.2 in severance and other personnel costs, $17.9 in facility-related costs, and $13.9 in contract termination costs. The charges were adjusted by the reversal of previously established liabilities of $33.1.

For the year ended December 31, 2024, the Company recorded net restructuring charges of $46.0. The charges were comprised of $43.0 in severance and other personnel costs and $5.9 in facility-related costs primarily associated with general integration activities. The charges were adjusted by the reversal of previously established liabilities of $2.9.

39

TABLE OF CONTENTS

Interest Expense

[[GREPCENT_TABLE]]
[["","Year Ended December 31,"],["","2025","","2024","","","","Change"],["Interest expense","$","224.1","","","$","208.3","","","","","7.6","%"]]
[[/GREPCENT_TABLE]]

For the year ended December 31, 2025, interest expense increased 7.6% as compared with the corresponding period in 2024. The increase was primarily due to higher weighted-average interest rates during the year ended December 31, 2025, when compared to the year ended December 31, 2024.

Equity Method Loss, Net

[[GREPCENT_TABLE]]
[["","Year Ended December 31,"],["","2025","","2024","","","","Change"],["Equity method loss, net","$","(13.3)","","","$","(1.4)","","","","","(866.3)","%"]]
[[/GREPCENT_TABLE]]

Equity method loss, net represents the Company’s ownership share in joint venture partnerships along with equity investments in other companies in the health care industry. The increase in Equity method loss, net for the year ended December 31, 2025, as compared with the corresponding period in 2024, was primarily due to the loss recognized from the SYNLAB investment that closed in the first quarter of 2025.

Other, Net

[[GREPCENT_TABLE]]
[["","Year Ended December 31,"],["","2025","","2024","","","","Change"],["Other, net","$","(55.0)","","","$","60.2","","","","","(191.4)","%"]]
[[/GREPCENT_TABLE]]

The change in Other, net for the year ended December 31, 2025, as compared to the year ended December 31, 2024, was primarily due to the TSA expiration resulting in a $76.2 decrease of fees charged to Fortrea for the year ended December 31, 2025, as compared with the corresponding period in 2024, related to the provision of administrative and information technology systems support. The costs to provide these transition services were included in Operating income, but the service fees were included in Other, net. In addition, there were net investment losses of $42.6, recorded during the year ended December 31, 2025, compared to net investment losses of $11.4 for the corresponding period of 2024, which are primarily driven by a decrease in the value of investments in other companies or investment funds that develop technology relating to the Company’s operations.

Provision for Income Taxes

[[GREPCENT_TABLE]]
[["","Year Ended December 31,"],["","2025","","2024"],["Provision for income taxes","$","229.8","","","$","212.4"],["Provision for income taxes as a percentage of earnings from operations before income taxes","20.7","%","","22.1","%"]]
[[/GREPCENT_TABLE]]

The decrease in the effective tax rate for the year ended December 31, 2025, as compared with the corresponding period in 2024, was primarily attributable to the release of specific uncertain tax positions.

40

TABLE OF CONTENTS

Results of Operations by Segment

[[GREPCENT_TABLE]]
[["","Year Ended December 31,"],["","2025","","2024","","Change"],["Dx segment operating income","$","1,779.9","","","$","1,606.3","","","10.8","%"],["Dx segment operating margin","16.4","%","","15.8","%","","0.5","%","(1)"],["BLS segment operating income","498.5","","","458.9","","","8.6","%"],["BLS segment operating margin","16.1","%","","15.7","%","","0.4","%"],["Segment operating income","2,278.4","","","2,065.2","","","10.3","%"],["General corporate and unallocated expenses","(482.2)","","","(670.8)","","","(28.1)","%"],["Amortization of intangibles and other assets","(280.0)","","","(256.4)","","","9.2","%"],["Restructuring and other charges","(127.2)","","","(46.0)","","","176.5","%"],["Goodwill and other asset impairments","(4.3)","","","(5.3)","","","(18.9)","%"],["Total Operating income","$","1,384.7","","","$","1,086.7","","","27.4","%"]]
[[/GREPCENT_TABLE]]

(1)Amount does not cross-foot due to rounding.

Dx segment operating income was $1,779.9 for the year ended December 31, 2025, an increase of 10.8% from operating income of $1,606.3 in the corresponding period of 2024, and Dx operating margin increased approximately 50 basis points year-over-year. The increase in operating margin was primarily due to increased organic revenue growth, including the performance of Invitae.

BLS segment operating income was $498.5 for the year ended December 31, 2025, an increase of 8.6% from operating income of $458.9 in the corresponding period of 2024, and BLS operating margin increased approximately 40 basis points year over year. The increase in operating margin was primarily due to increased organic revenue growth and operating efficiencies, partially offset by higher personnel costs.

General corporate expenses are comprised primarily of administrative services, such as executive management, human resources, legal, finance, corporate affairs, and information technology. Corporate expenses were $48

[Excerpt truncated for page length; the complete text is on the linked full-MD&A page.]

Read the full FY 2025 MD&A: /company/LH/mda/fy2025/
All MD&A years: /company/LH/mda/


## MD&A history

Prior-year 10-K MD&A spans are extracted from SEC filings with the same bounded parser used for the latest filing. Each year's full verbatim text is on its own sub-page.

- [FY 2024 MD&A](/company/LH/mda/fy2024/): filed 2025-02-25; accession 0000920148-25-000032 (https://www.sec.gov/Archives/edgar/data/920148/000092014825000032/lh-20241231.htm)
- [FY 2023 MD&A](/company/LH/mda/fy2023/): filed 2024-02-26; accession 0000920148-24-000014 (https://www.sec.gov/Archives/edgar/data/920148/000092014824000014/lh-20231231.htm)
- [FY 2022 MD&A](/company/LH/mda/fy2022/): filed 2023-02-28; accession 0000920148-23-000017 (https://www.sec.gov/Archives/edgar/data/920148/000092014823000017/lh-20221231.htm)
- [FY 2021 MD&A](/company/LH/mda/fy2021/): filed 2022-02-25; accession 0000920148-22-000015 (https://www.sec.gov/Archives/edgar/data/920148/000092014822000015/lh-20211231.htm)




## Macro cross-references

Indicators mapped to this company's SIC classification (industry 8071 Services-Medical Laboratories) by grepcent's deterministic macro-sector crosswalk. A navigational mapping, not a statistical or causal claim.

- [PCE](/indicator/PCE/): Personal Consumption Expenditures
- [GDPC1](/indicator/GDPC1/): Real Gross Domestic Product
- [PAYEMS](/indicator/PAYEMS/): All Employees, Total Nonfarm
- [CES0500000003](/indicator/CES0500000003/): Average Hourly Earnings of All Employees, Total Private
- [UNRATE](/indicator/UNRATE/): Unemployment Rate
- [DSPIC96](/indicator/DSPIC96/): Real Disposable Personal Income

Macro-to-micro threads including this sector: [US labor market](/thread/us-labor-market/), [Growth & output](/thread/growth-output/), [Government finances](/thread/government-finances/), [Sector employment](/thread/sector-employment/).

All macro indicators: /indicators/


## For LLMs & downloads

Markdown twin: /company/LH.md · JSON record: /company/LH.json · verified financials: /company/LH/financials.json / /company/LH/financials.csv · machine TOC for the whole site: /llms.txt